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Abstract 
C-Kit (CD117), the receptor for the stem cell
factor, a growth factor for melanocyte migra-
tion and proliferation, has shown differential
immunostaining in various benign and malig-
nant melanocytic lesions. The purpose of this
study is to compare c-Kit immunostaining in
benign  nevi  and  in  primary  and  metastatic
malignant melanomas, to determine whether
c-Kit can aid in the differential diagnosis of
these lesions. c-Kit immunostaining was per-
formed  in  60  cases  of  pigmented  lesions,
including 39 benign nevi (5 blue nevi, 5 intra-
dermal nevi, 3 junctional nevi, 15 cases of pri-
mary  compound  nevus,  11  cases  of  Spitz
nevus),  18  cases  of  primary  malignant
melanoma  and  3  cases  of  metastatic
melanoma.  The  vast  majority  of  nevi  and
melanomas examined in this study were posi-
tive  for  c-Kit,  with  minimal  differences
between benign and malignant lesions. C-Kit
cytoplasmatic  immunoreactivity  in  the
intraepidermal proliferating nevus cells, was
detected in benign pigmented lesions as well
as  in  malignant  melanoma,  increasing  with
the age of patients (P=0.007) in both groups.
The patient’s age at presentation appeared to
be  the  variable  able  to  cluster  benign  and
malignant pigmented lesions. The percentage
of c-Kit positive intraepidermal nevus cells was
better associated with age despite other vari-
ables (P=0.014). The intensity and percentage
of  c-Kit  positivity  in  the  proliferating  nevus
cells in the dermis was significantly increased
in  malignant  melanocytic  lesions  (P=0.015
and  P=0.008)  compared  to  benign  lesions
(compound    melanocytic  nevi,  Spitz  nevi,
intradermal nevi, blue nevi). Immunostaning
for c-Kit in metastatic melanomas was nega-
tive. Interestingly in two cases of melanoma
occurring  on  a  pre-existent  nevus,  the
melanoma tumor cells showed strong cytoplas-
matic and membranous positivity for c-kit, in
contrast with the absence of any immunoreac-
tivity in pre-existent intradermal nevus cells.
C-Kit does not appear to be a strong immuno-
histochemical  marker  for  distinguishing
melanoma from melanocytic nevi, if we consid-
er c-Kit expression in intraepidermal prolifer-
ating cells. The c-Kit expression in proliferat-
ing melanocytes in the dermis could help in
the differential diagnosis between a superfi-
cial spreading melanoma (with dermis inva-
sion) and a compound nevus or an intradermal
nevus. Finally, c-Kit could be a good diagnostic
tool for distinguishing benign compound nevi
from malignant melanocytic lesions with der-
mis  invasion  and  to  differentiate  metastatic
melanoma from primary melanoma.
Introduction
C-Kit is a transmembrane receptor tyrosine
kinase that binds stem cell factor (SCF).1-3 C-
Kit is encoded by the kit proto-oncogene, local-
ized to human chromosome 4 and to mouse
chromosome 5.4,5 The c-Kit/SCF interaction is
critical  for  the  survival  and  development  of
stem cells involved in hematopoiesis,6 in pan-
creas  development7 and  in  melanogenesis.8
The c-Kit gene product is expressed in several
normal  cell  types  including  mast  cells,  the
interstizial cells of Cajal and the melanocytes
and epithelial cells of the breast.9 Alterations
in c-Kit expression are seen in a variety of neo-
plasms  including  mastocitosis,  gastrointesti-
nal cell tumors (GISTs) and germ cell tumors.10
After  binding  to  the  stem  cell  factor,  c-Kit
begins a signal cascade that contributes to the
growth  and  differentiation  of  multiple
hematopoietic  lineages.11 Previous  studies
have shown that c-Kit is expressed in junction-
al components of benign compound nevi12 and
it is frequently positive in superficial spread-
ing melanoma (early stage);13 this positivity is
lost in the vertical growth phase of invasive
melanoma.14-17 More interestingly, a loss of c-
Kit immunostaining from primary malignant
melanoma  to  metastatic  melanoma  in  the
same patients has been reported.18 Malignant
transformation  of  melanocytes  is  associated
with  changes  in  the  expression  of  c-Kit.
Several  studies  have  demonstrated  that  the
progression of human melanoma is associated
with the loss of expression of c-Kit.8,14,15 These
studies revealed that expression of the tyro-
sine  kinase  receptor  encoded  by  the  c-Kit
proto-oncogene  gradually  declines  during
growth and invasion of human melanoma.8,14-16
The explanation for the loss of c-Kit expression
in  melanoma  progression  has  still  not  been
fully explained. Since SCF plays a crucial role
in melanocyte proliferation, there is an inter-
est in the diagnostic or treatment potentials of
c-Kit  in  melanocytic  lesions,  especially  in
melanoma. Given the heterogeneous appear-
ance of malignant melanoma, diagnostic diffi-
culties19 and poor inter-observer reproducibili-
ty, this study was designed to assess whether
the expression of c-Kit identifies differences
in  melanocytic  lesions,  considering  benign
nevi,  primary  melanoma  and  metastatic
melanoma.
Materials and Methods
A retrospective study was initiated to review
the medical records of all patients with a diag-
nosis  of  benign  nevus  and  malignant
melanoma  between  2008  and  2009  at  the
Anatomy  Pathology  Division,  University  of
Cagliari,  Italy.  Through  a  careful  clinical-
pathological correlation, we identified 60 cases
of pigmented lesions grouped into 39 cases of
benign nevus (5 blue nevi, 5 intradermal nevi,
3  junctional  nevi,  15  cases  of  primary  com-
pound  nevus,  11  cases  of  Spitz  nevus),  18
cases  of  primary  melanoma  and  3  cases  of
metastatic  melanoma.  Five  micron  paraffin
sections  from  benign  and  malignant
melanocytic lesions were immunostained for
CD117,  c-Kit,  (cod,A4502  polyclonal  rabbit
anti-Human CD117, c-Kit, DAKO, Carpinteria,
CA, USA), diluted 1:200. The incubation time
of  the  primary  antibody  was  30  min.  Heat
induced antigen retrieval was adopted (20 min
at 98° in Tris/edta pH9). We used the Dako
cytomation LSAB2 system-HRP (DAKO) that is
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based  on  a  modified  labelled  avidin-biotin
(LAB) technique in which a biotinylated sec-
ondary antibody forms a complex with peroxi-
dase-coniugated  strepavidin  molecules.
Endogenous peroxidase activity was quenched
by  incubating  (5  min)  specimens  with  3%
hydrogen peroxide. The staining was complet-
ed  after  incubation  (10  min)  with  3-amino-
9.ethyl carbazole (AEC) substrate chromogen,
which resulted in a red-colored precipitate at
the antigen site. Slides were reviewed by two
pathologists who were not aware of the clinical
data, and evaluated it for both tumor cell per-
centage  and  intensity  of  immunoreactivity.
The percentage of positive cells was recorded
as 0=negative; 1=<5% of cells staining; 2=5-
50% of cells staining; 3=51-95% of cells stain-
ing; and 4=>95% of cells staining.20 Intensity
was  scored  as  0  (negative),  1+  (weak),  2+
(moderate), and 3+ (strong), and evaluated by
comparing contiguous epidermal melanocytes
and interstitial mast cells (considering moder-
ately  positive  contiguous  melanocytes  (2+)
and intensely positive (3+) dermal mast cells).
The product of the percentage and the intensi-
ty score was used as the final measure of the
staining. Differences in c-Kit immunoreactivi-
ty in the top and in the bottom of lesions were
as well evaluated. Further variables considered
in  the  present  study  were:  maximal  dimen-
sions of lesions, age and sex of patients. 
Statistical analysis
The variables involved in the analysis are
semiquantitative,  more  precisely  they  are
ordered  polytomous  categorical  values.  This
means that, if we consider, for example, two
values for the percentage of positive cells, say
1 and 2, these values represent two sets of per-
centages, less than 10% and between 10 and
50%. Therefore, the difference between values
1 and 2 cannot be evaluated simply on a linear
scale by saying, for instance, that it is 1. In
order  to  estimate  the  relationship  between
scores (percentage of positive cells and inten-
sity) and all other variables, it is more appro-
priate  to  use  the  proportional  odds  model.21
The P-values are obtained with the use of the
proportional odds model. Essentially this is a
generalization  of  the  regression  model  suit-
able  for  polytomous  data.  For  a  given  score
variable,  different  regression  models  can  be
estimated according to the chosen explanatory
variables.  We  come  up  with  the  best  model
according to the Deviance Criteria.21The P-val-
ues, in the Results section, illustrate the sig-
nificance levels of the regression coefficients
that relate the score to the specified variable.
The pre-selected significance is 5%. Only for
the sake of comparison did we report t-tests
using Welch correction, to assess the signifi-
cance of the relation between a score variable
and  the  group  of  pigmented  lesions.  Such
analyses  were  appropriate  if  the  collected
score variables (and even their product) were
interpretable under a linear scale. The data are
presented as mean ± SEM.
Results 
Clinical-pathological features of
melanocytic lesions
Clinical  features  of  melanocytic  lesions,
recruited in our study, are presented in Table
1.  The  5  blue  nevi  were  from  5  subjects  (4
males and 1 female) ranging from 14 to 77
years-old (mean age 45.8). Histologically, they
were characterized by the presence of elongat-
ed melanocytes with thin, pigmented cytoplas-
matic  dendrites  scattered  between  undis-
turbed collagen fibers and a variable number of
melanophages. The 18 melanomas included 1
in situ melanoma from a 75 years-old female, 3
in situ melanoma from 3 females ranging from
46 to 76 years-old (mean age 59), 14 superfi-
cial spreading melanomas from 14 subjects (6
males and 8 females) ranging from 25 to 78
years-old  (mean  age  42.8)  (Table  2).
Histologically,  they  were  characterized  by
asymmetric  proliferations  of  atypical
melanocytes associated with occasional page-
toid spread, mitotic activity and inflammatory
reaction. Primary cutaneous melanomas were
invasive with Clark’s levels ranging from II to
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Table 1. Clinical data.
No. Sex  Age  Mean Anatomical site
(M:F) range  age
(years) (years)
BluNevi 5 4:1 14-77 45.8 Foot, arm, scalp(3)
Acral melanoma 1 0:1 --Foot
Melanoma in situ 3 3:0 46-76 59 Back, thorax, foot
Supeficial spreading  14 6:8 25-78 42.8 arm, back (6), thigh, 
melanoma leg(3), breast, thorax, abdomen
Metastasis 3 3:0 59-77 69.6 Wrist, abdomen, lynphonode
Dermal nevi 5 2:3 19-30 26.4 Vulva, back, abdomen, scalp, neck
Junctional nevi 3 0:3 33-34 33.3 Back, leg, foot
Compound nevi 15 7:8 21-60 32.6 back(8), thorax, abdomen(2), leg, 
pube, shoulder, temple,
Spitz nevi 11 3:8 3-50 20,2 arm(3), leg(2), hand(2), shoulder,
high, back(2)
Table 2. Characteristics of eighteen primary cutaneous melanomas.
Type Clark Breslow Radial phase Vertical phase Site
1 acral II 1.2 + Foot
2 SSM IV 1.1 + Back
3 SSM II 0.5 + Abdomen
4 SSM IV 1.6 + Arm
5 in situ I/ / / Back
6 SSM II 0.6 + Leg
7 SSM IV 0.8 + Back
8 SSM II 0.2 + Back
9 SSM IV 1.0 + Thigh
10 in situ I/ / / Thorax
11 SSM IV 1.0 + Leg
12 SSM II 0.5 + Breast
13 in situ I/ / / Foot
14 SSM II 0.2 + Leg
15 SSM IV 0.7 + Back
16 SSM II 0.2 + Back
17 SSM II 0.3 + Back
18 SSM IV 2.8 + Thorax
SSM, superficial spreading melanoma.[European Journal of Histochemistry 2011; 55:e20] [page 107]
IV, and Breslow depths ranging from 0.5 up to
2.8 mm (Table 2). The 3 metastasis were from
3 male subjects, ranging from 59 to 77 years-
old  (mean  age  69.6).  The  23  benign  nevi
include 3 junctional types from 3 females rang-
ing  from  33  to  34  years-old;  5  dermal  types
from 5 subjects (2 males and 3 females) rang-
ing from 19 to 30 years-old (mean age 26.4), 15
compound types from 15 subjects (7 males and
8  females)  ranging  from  21  to  60  years-old
(mean  age  32.6).  Histologically,  junctional
nevi were characterized by small melanocytes
without cytological atypia, organized both in
regular aggregates at basis of rete ridges or in
lentiginous fashion at dermo-epidermal junc-
tion; intradermal nevi were characterized by
banal  melanocytes  organized  in  aggregates
with  regular  maturation.  The  11  Spitz  nevi
included: 5 junctional types and 6 compound
types from 11 subjects (3 males and 8 females)
ranging  from  3  to  50  years  old  (mean  age
20.2).  Histologically  they  were  characterized
by  spindle  and  epithelioid  melanocytes
arranged in fascicles or nests with clefting and
occasional  central  spread  of  melanocytes.
Patients with benign melanocytic lesions were
younger  (29.6±2.6)  than  patients  with
melanoma  (47.8±3.8)  and  patients  with
metastatic  melanoma  (69.7±5.4).  The  mean
Breslow  thickness  for  melanomas  was
0.85±0.18 and it has never entered into the
statistical analysis (Table 2).
C-Kit expression by immunohisto-
chemistry
Available  data  of  the  c-Kit  immunohisto-
chemical staining are presented in Tables 3
and 4. Table 3 summarizes the values of c-Kit
intensity staining and Table 4 summarizes the
values  of  percentage  of  c-Kit  positive  nevus
cells. All 5 blue nevi showed slight cytoplasmat-
ic-membranous positivity of fusate nevus cells
with  percentage  of  c-Kit  stained  cell  <5%,
without difference of c-Kit immunohistochem-
ical expression between the top and bottom of
lesions. As for the 18 cases of melanoma, the 3
cases of melanoma in situ, one case showed
slight (1+) cytoplasmatic positivity with c-Kit
stained cell percentage <5%, the second case
showed moderate membranous positivity (2+)
with c-Kit stained cell percentage 51-95 % and
the third case (acral type) showed strong (3+)
positivity with both membranous and cytoplas-
matic pattern, with percentage of c-Kit stained
cell >95%. 
The  acral  melanoma  showed  strong  cyto-
plasmatic positivity (3+), with percentage of c-
Kit stained cell >95% in the junctional compo-
nent;  c-Kit  expression  in  dermal  component
was moderate (2+) cytoplasmatic, with c-Kit
stained cell percentage 51-95%, without sub-
stantial  difference  between  the  top  and  the
bottom of lesions. The 14 cases of superficial
spreading melanoma, showed slight cytoplas-
matic positivity in the junctional component
(1+) in two cases; moderate intensity (2+) in
7 cases (5 cytoplasmatic, 2 both cytoplasmatic
and membranous); strong positivity (3+) in 6
cases  (4  expressed  both  cytoplasmatic  and
membranous pattern and 2 only cytoplasmat-
ic), with percentage of c-Kit stained cell > 5%
in  one  case,  between  5-50%  in  5  cases,
between  51-95%  in  3  cases  and  >95%  in  5
cases.  The  intensity  of  c-Kit  stained  dermal
cell  was slight (1+) in 5 cases (5 cytoplasmat-
ic); moderate intensity (2+) in 4 cases (4 cyto-
plasmatic and 2 with cytoplasmatic and mem-
branous  pattern);  strong  intensity  (3+)  in
only one case (both cytoplasmatic and mem-
branous  pattern);  with  percentage  of  c-Kit
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Table 3. Immunohistochemical data. 
Intensity c-Kit staining in tumors cells
Epidermis Dermis
Negative Weak Moderate Strong Negative Weak Moderate Strong
n. 01 23 0 1 2 3
BluNevi 50 0 0 0 - 5 - _
Acral melanoma 10 0 0 0 0 1 0
Melanoma in situ 30 1 1 1 0 0 0 0
Supeficial spreading melanoma 14 02 75 4 5 4 1
Metastasis 3- - - - 3 0 0 0
Dermal nevi 50 0 0 0 1 2 1 1
Junctional nevi 30 0 0 3 - - - -
Compound nevi 15 02 10 34 8 2 1
Spitz nevi 11 0 10 10 3 3 0 0
Table 4. immunohistochemical data.
Percentage of tumors cells expressing c_Kit
Epidermis Dermis
Negative <5% 5-50% 51-95% >95% Negative <5% 5-50% 51-95% >95%
n. 0123 0 1 2 3
BluNevi 5- - - - - 0 5 0 0 0
Acral melanoma 10 0 0 0 1 0 0 0 1 0
Melanoma in situ 30 1 0 1 1 - - - - -
Supeficial spreading melanoma 14 0153 5 3 3 4 4 0
Metastasis 3- - - - - 3 0 0 0 0
Dermal nevi 5- - - - - 1 2 1 1 0
Junctional nevi 30 0 1 1 1 - - - - -
Compound nevi 15 0068 1 4 3 6 2 -
Spitz nevi 11 0344 0 3 2 1 0 0[page 108] [European Journal of Histochemistry 2011; 55:e20]
stained dermal cell <5% in 3 cases, between 5-
50% in 3 cases and 51-95% in 4 cases. The top-
bottom evaluation  showed  seven  cases  with
diffuse  positivity  without  differences  in  the
lesions;  three  cases  showed  evident
immunoreactivity  on  the  top  with  gradual
decrease  to  the  bottom  of  lesions.  C-kit
immunoreactivity was negative in 3 cases of
metastatic melanoma. The 3 cases of junction-
al nevus showed strong c-Kit positivity (3+) (2
membranous,  1  cytoplasmatic)  with  c-Kit
stained cell percentage equal to 5-50% in one
case, 51-95 % in another case and >95% in the
last  one.  The  15  primary  compound  nevus,
showed slight epidermic membranous, positiv-
ity (1+) in 2 cases, moderate intensity (2+) in
10 cases (5 membranous and 5 cytoplasmatic)
and  strong  membranous  positivity  (3+)  in
three cases. The percentage of c-Kit stained
cell (Table 4) in the epidermis were between 5-
50% in 6 cases, between 51-95% in 8 cases and
>95% in one case. The c-Kit immunoreactivity
in the dermic component (Table 3) was slight
(1+) in 8 cases (cytoplasmatic), moderate pos-
itivity  (2+)  in  two  cases  (membranous),
strong  (3+)  in  one  cases  (cytoplasmatic),
absent  in  four  cases.  The  percentage  c-Kit
stained cell in the dermic component (Table 4)
was <5% in three cases and between 5-50% in
six cases; 51- 95% in two cases, absent in four
cases. The top-bottom evaluation showed in 11
cases evident c-Kit positivity in the top with
gradual reduction to bottom of lesions whereas
in the remaining four cases c-Kit immunoreac-
tivity  was  homogeneous  and  diffused  to  all
areas of lesions. In the 5 intradermal nevi, c-
Kit immunoreactivity in the dermic component
(Table 3) was slight (1+) in two cases (cito-
plasmatic and membranous in one case, only
citoplasmatic in the other one), moderate (2+)
in one case (citoplasmatic and membranous),
strong  (3+)  in  one  case  (membranous),
absent in one case. The percentage of c-Kit
stained cell was <5% in two cases and between
5-50% in one case; 51-95% in one case, absent
in the last case. The top-bottom evaluation was
not performed for the absence of the epidermic
component. As for the 11 cases of Spitz nevus
(5 junctional and 6 compound), the junctional
Spitz nevi showed slight positivity (1+) in 4
cases  and  moderate  positivity  (2+)  in  one
case;  the  c-Kit  stained  cell  percentage  was
between 5-50% in 3 cases, and 51-95% in the
two  remaining  cases.  All  6  compound  Spitz
nevi  showed  slight  epidermic  positivity  (2
membranous  and  4  cytoplasmatic),  the  per-
centage  of  c-Kit  stained  cell  was  <5%  in  3
cases, 5-50% in one case, 51-95% in two cases.
The  dermic  immunoreactivity  for  c-Kit  was
slight (1+) in three cases (cytoplasmatic) with
c-Kit stained cell percentage <5% in two cases
and between 5-50% in one case, absent in the
remaining three cases. The top-bottom evalua-
tion in the six compound Spits nevi showed
evident c-Kit positivity on top with a gradual
decrease to bottom of the lesions in all cases.
The  vast  majority  of  nevi  and  melanomas
examined in this study were positive for c-Kit,
with  minimal  differences,  at  microscopic
observation,  between  benign  and  malignant
lesions and with a decrease of c-Kit expression
from top to bottom of the lesions. C-Kit was
equally expressed in the junctional component
of  any  melanocytic  lesions  both  benign  and
malignant (Figures 1 and 2). Differences were
found in c-Kit immunoreactivity between the
intradermal component of benign and malig-
nant  melanocytic  lesions.  In  particular,  in
superficial  spreading  melanoma  with  initial
dermal  invasion,  radial  growth  phase,
immunostaning  for  c-Kit  showed  higher
grades of intensity and a higher percentage of
positive melanocytic cells (Figure 3; Table 3
and  4).  On  the  contrary  in  compound  nevi,
immunostaning was stronger in the junctional
component, with a progressive decrease from
the top to bottom of the lesion (Figure 4). C-kit
staining  of  the  intraepidermal  nevus  cells
demonstrated a cytoplasmic pattern admixed
with a membranous pattern. According to the
proportional odds model, there was a signifi-
cant association between the intensity of c-Kit
staining in intraepidermal nevus cells and the
increasing age of the patient (P=0.007) (Table
5).  Also  the  percentage  of  c-Kit-positive
intraepidermal nevus cells resulted positively
considering  the  patient’s  age  increasing
(P=0.014) (Table 5); in one case, we observed
that the intensity and percentage of positive
intraepidermal nevus cell was related to the
diameter  of  the  lesion.  Intensity  of  c-Kit
expression in dermal melanocytes was signifi-
cantly  higher  in  the  melanoma  group  com-
pared to the benign lesion group (P=0.015), as
well as the percentage of c-Kit-positive dermal
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Figure 1. Representative staining results in a case of compound nevus. A) H&E staining
showing a proliferation of junctional and dermal melanocytes with symmetrical pattern
and no evidence of cytological dysplasia; B) C-Kit immunohistochemistry showing strong
(membranous and cytoplasmatic) expression in the junctional component of compound
nevus and weak expression in the dermal component with gradual decrease to the bottom
of the lesion. In the reticular dermis frequent c-Kit positive mastcell. Scale bars: 100 µm.
Figure 2. Representative staining results in an interesting case of superficial spreading
melanoma on a compound nevus. A) H-E stain showing an in situ superficial spreading
melanoma (left) and a compound nevus with a symmetrical pattern and no evidence of
cytological dysplasia; B) Prominent CD 117 immunohistochemical staining only at der-
moepidermal junction and focal positivity of bottom in the dermal component of com-
pound nevus; C) CD 117 immunohistochemical staining only at dermoepidermal junc-
tion of in situ superficial spreading melanoma; D) CD 117 immunohistochemical stain-
ing focal positivity at the bottom of the dermal component of compound nevus. A,B, scale
bars 200 µm; C,D, scale bars: 20 µm.[European Journal of Histochemistry 2011; 55:e20] [page 109]
melanoma  cells  (P=0.008)  (Table  5).
Interestingly,  dermal  staining  of  metastatic
melanoma  was  negative  (Figure  5).  These
final  models  (represented  in  Table  5)  were
obtained after considering age, type, sex and
dimension of lesions in order to account for
possible confounders. For the sake of compari-
son, in Table 6 we report the analysis using
product staining and t-test with Welch correc-
tion as performed by Zhu et al.22 For instance,
association  between  expression  in  dermal
melanocytes in the melanoma group compared
to benign lesion has a P-value of 0.032, which
is higher than 0.015 (Table 5 and 6). Finally,
we also reported no association between epi-
dermal  melanocytes  in  the  melanoma  group
compared  to  benign  lesions  with  a  P-value
much higher than 0.057 (either in intensity or
percentage).
Discussion
Benign  melanocytic  nevi  may  have  occa-
sional cosmetic significance but, for the most
part,  they  are  important  only  in  relation  to
melanoma. Nevi are the most important simu-
lants of melanoma, both clinically and histolog-
ically, and can usually be reliably distinguished
from  melanoma  using  published  criteria.
Some  benign  lesions  are  characterized  by  a
greater degree of atypia and may be more dif-
ficult  to  diagnose.19 Malignant  melanoma
remains the most contentious of all diagnoses
in dermatophatology. While classic histologic
criteria have been extensively described over
the  past  four/five  decades,  interpretation  of
these criteria remains difficult.23,24 Currently,
separation of melanomas from nevi is based
primarily on light microscopic interpretation
of  hematoxylin  and  eosin-stained  sections,
with limited assistance from immunohistology.
The  heterogeneous  histological  features  of
melanoma may often overlap with melanocytic
nevi. For this reason, pathologists have looked
to immunohistochemistry to assist with diffi-
cult cases. In this challenging diagnostic sce-
nario, many studies have been performed to
identify molecular markers that might distin-
guish  benign  lesions  from  malignant
melanocytic ones and also the various progres-
sion stages in primary malignant melanoma of
the skin.25,26 C-Kit immunoreactivity has been
proposed as a useful tool in the differential
diagnosis between deep soft tissue or visceral
lesions with melanocytic differentiation; posi-
tive staining for c-Kit could exclude the diag-
nosis of clear cell sarcoma, but it is compatible
with the diagnosis of metastatic melanoma.27
Kashani-Sabet et al. run some transcriptome
analyses that show the differential expression
of several genes in melanoma progression.28
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Table 5. Results with the proportional odds model (Coefficient ± Standard Error, P-
value).  The  first  column  indicates  the  specific  model  in  terms  of  Dependent
Variable/Explanatory Variable. Such models have been chosen according to the Deviance
Criteria. 
Model Coefficient ± Standard Error, P-value of explanatory variables
Age* Pigmented lesions**
Epi.Int | Age -0.05±0.02, P=0.007
Epi.Perc | Age -0.04±0.02, P=0.014
Der.Int | Pigmented lesions -1.82±0.73, P=0.015
Der.Perc | Pigmented lesions -1.89±0.70, P=0.008
*Negative coefficients indicate increase with respect to age;**negative coefficients indicate increase in malignant vs. benign
lesions.Epi.Int, epidermal melanocytes intensity of c-Kit stain; Epi.Per., epidermal melanocytes percentage of c-Kit stain; Der.Int.,
dermal melanocytes intensity of c-Kit stain; Der.Perc., dermal melanocytes percentage of c-Kit stain.
Table 6. Results of CD117 immunohistochemical product staining (mean ± SEM, P-
value); the P-value refers to the significance of the difference between benign and malig-
nant pigmented lesions for column benign; malignant and metastatic for column malig-
nant; metastatic and benign for column metastatic. Such significance values are calculat-
ed with the usual t-test.
Benign Primary malignant Metastatic
nevus melanoma melanoma
Number of cases 39 18 3
Epidermal melanocytes 4.7±0.5, P=0.057 7.0±1.0, n.a. n.a., n.a.
Dermal melanocytes 1.8±0.4, P=0.032 4.0±0.8, P<0.001 0±0, P<0.001
n.a., not available.
Figure 3. Representative staining in a case of superficial spreading melanoma (vertical
growth phase). A) H&E staining showing a melanocytic proliferation with architectural
disorder; B) prominent c-Kit immunostaining both at the junctional and dermic compo-
nent. Scale bars: 200 µm.
Figure 4. Representative staining in a case of Spitz nevus. A) H&E staining showing a pro-
liferation of spindle and epitelioid melanocytes with symmetrical pattern and no evidence
of cytological dysplasia; B) prominent c-Kit immunohistochemical staining at dermoepi-
dermal junction and progressive decrease positivity in the dermis. Scale bars: 200 µm.[page 110] [European Journal of Histochemistry 2011; 55:e20]
They also performed a multi-marker diagnostic
assay  using  5  markers  (ARPC2,  FN1,  RGS1,
SPP1 and WNT2), which are over-expressed in
melanoma  cells.  Gould  Rothberg  et  al.  pro-
posed that the ratio of nuclear to non-nuclear
HMB45 immunofluorescence staining may be
useful  in  the  diagnosis  of  melanocytic
lesions.29 Recent  data  has  shown  also  that
PAX3  is  commonly  expressed  in  primary
melanoma samples (21/58), but significantly
less  frequently  in  benign  pigmented  lesions
(9/75).30 Additionally,  IMP-3  (insulin-like
growth factor-II messenger RNA-binding pro-
tein-3) may have diagnostic utility in distin-
guish melanoma from benign nevi, displastic
nevi and Spitz nevi.31 Zhu et al. proposed that
CD117 is unlikely to be a useful diagnostic tool
to  differentiate  Spitz  nevus  from  malignant
melanoma but may be useful to differentiate
metastatic melanoma from primary melanoma
in patients who have a history of melanoma
and who presented with new dermal lesions.22
Increased  Wilms’  tumor  1  protein  (WT1)
expression has been proposed as a marker of
melanoma  cells.  However,  as  a  single
immunostaining marker, WT1 is not sufficient
to  distinguish  melanoma  from  benign
melanocytic nevi.32 Hillard et al. retained that
the staining pattern for p16 in desmoplastic
melanomas and Spitz nevi, in conjunction with
the  histopathologic  features,  S100  staining,
Ki67 proliferation index and clinical scenario
may aid in the difficult differential diagnosis
between  these  two  entities.33 Ribè  and  Scot
McNutt  assessed  an  immunohistochemical
test for S100A6 protein to differentiate Spitz
nevi from melanoma and melanocytic nevi:34
this marker can be used when the distinction
is  very  difficult  or  controversial  in  routine
studies, especially when there is a junctional
component.  CD117  is  an  indicator  of  malig-
nant  proliferative  process  and  reported  that
while 59% of benign melanocytic nevi express
c-Kit, 100% of displastic nevi and 96% of pri-
mary melanoma express c-Kit.8 In our study,
we observed that c-Kit, in the junctional com-
ponent  of  benign  and  malignant  lesions,  is
constantly  expressed,  with  minimal  differ-
ences between intensity and percentage, while
in the dermal component of both benign nevi
and melanomas there is a decrease in expres-
sion  of  c-Kit.  In  metastatic  melanoma  with
only dermal component, c-Kit expression was
absent or minimally present as well as been
reported by Zhu et al. and Guerriere et al.22,25
Besides a decrease of c-Kit expression in the
intradermal component of pigmented lesions,
our statistical data showed  higher values of
the intensity and of the percentage c-Kit posi-
tive cells in melanomas. Our study suggests
that c-Kit is not a specific marker discrimina-
tor between junctional component of benign
melanocytic  nevi  and  superficial  spreading
melanoma. In fact the intensity and percent-
age of c-Kit in intraepidermal melanocytes was
not  correlated  with  the  type  of  pigmented
lesions (benign melanocytic nevi and superfi-
cial spreading melanoma). In fact also in junc-
tional nevi, compound nevi, and Spitz nevi, the
intraepidermic  melanocytes  showed  intense
and diffuse c-Kit positivity as well as the prolif-
erant melanocytes of melanoma in situ and of
superficial spreading melanoma. At microscop-
ic  analysis  we  observed,  in  the  intradermic
component of pigmented lesions, that intensi-
ty and percentage of c-Kit positive cells was
higher  in  melanomas  than  in  nevi,  this  is
moreover proved by statistical analysis. It was
speculated that in the model of tumor progres-
sion  in  malignant  melanoma  (atypical
intraepidermic proliferation followed by a radi-
al growth phase then a vertical growth phase)
to acquire proliferative advantage and escape
from  epidermal  boundaries,  melanoma  cells
should lose Kit expression.35 This hypothesis
was  supported  by  previous  observations  in
which Kit expression in melanoma was strong
in the melanoma in situ and in the junctional
component  of  invasive  lesions,  but  was  lost
once  the  melanoma  became  invasive  and
metastatic.15,25 Also  our  data  supported  this
intriguing hypothesis, in fact our superficial
spreading  melanomas,  in  radial  phase  or  in
vertical phase, even though with an intensity
and percentage of c-Kit positive dermic nevus
cells  higher  than  in  the  benign  intradermic
and  compound  nevi,  showed  an  initial
decrease of c-Kit expression from the top to
the bottom of lesions. Only one case of super-
ficial  spreading  melanoma,  in  the  vertical
growth phase, showed diffuse and intense c-
Kit positivity (Figure 3). Also the real loss of c-
kit expression in our three metastasis corrob-
orate  this  hypothesis.  Marked  intensity  in
junctional components and gradual decrease
of  c-Kit  expression  in  dermal  component  is
observed both in intradermal and compound
nevi, up to range a real loss of c-Kit expression
in the bottom of lesions, as was observed in
melanomas. We supposed that, in benign nevi,
this  junctional  marked  c-Kit  intensity  with
gradual decrease in dermal component, could
be explained as result of a motogen effect.35 C-
Kit expression could indicate melanocytes dur-
ing  their  migration  phase.  Therefore,  the
migratory direction in melanocytic lesions is
from  dermis  to  epidermis.35 We  additionally
observed a real c-Kit over-expression in two
cases of acral melanoma, even if Kit mutation
is not tested. This observation is not in con-
trast to literature data. Curtin et al. found that
more than a third of the acral, mucosal and sun
induced  melanomas  without  detectable  Kit
mutation  or  copy  number  increase,  showed
over-expression of Kit by immunohistochem-
istry led to hypothesize that other mechanisms
than  gene  mutation  or  amplification  could
explain the observed Kit over-expression.36 In
our study, variables like intensity and percent-
age  increased  only  if  correlated  with  the
patient’s age. However, scores of intensity and
percentage  of  c-Kit,  only  in  dermal
melanocytes  resulted  statistically  different
between benign and malignant lesions: those
variables were more expressed in melanoma
cells than in nevus cells. In summary on the
basis of our data, c-Kit should not be consid-
ered as an indicator of malignant proliferative
process but may be considered as a result of
the  motogenic  effect  of  proliferating
melanocytes. It could further be a useful mark-
er  to  differentiate  primary  melanoma  from
compound nevi while seeming to be not entire-
ly useful to differentiate melanocytic junction-
al nevi from melanoma in situ or superficial
spreading melanoma in radial phase. 
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